287393-39-9Relevant articles and documents
Palladium-Catalyzed Synthesis of Bis-Substituted Sulfoxonium Ylides
Janot, Christopher,Palamini, Pierre,Dobson, Benjamin C.,Muir, James,A?ssa, Christophe
, p. 296 - 299 (2019)
The lack of general access to bis-substituted sulfoxonium ylides is addressed by developing a palladium-catalyzed C-H cross-coupling of α-ester sulfoxonium ylides with (hetero)aryl iodides, bromides, and triflates. Three different catalysts have been eval
Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-α converting enzyme and matrix metalloproteinase inhibitors
Venkatesan, Aranapakam M.,Davis, Jamie M.,Grosu, George T.,Baker, Jannie,Zask, Arie,Levin, Jeremy I.,Ellingboe, John,Skotnicki, Jerauld S.,DiJoseph, John F.,Sung, Amy,Jin, Guixian,Xu, Weixin,McCarthy, Diane Joseph,Barone, Dauphine
, p. 6255 - 6269 (2007/10/03)
A series of 4-alkynyloxy phenyl sulfanyl, sulfinyl and sulfony alkyl and piperidine-4-carboxylic acid hydroxamides were synthesized. Their structure-activity relationships, against tumor necrosis factor-α (TACE) and matrix metalloproteinase (MMP) inhibito
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
-
Page column 62, (2008/06/13)
Compounds of the formula are useful in treating disease conditions mediated by TNF-α, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.